EBMT 2020 | FLAMSA-reduced intensity vs myeloablative conditioning for R/R AML with disease at transplantation

Eduardo Rodríguez-Arbolí, MD, MPhil, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain, discusses FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with active disease at transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).